Renalyx unveils world’s first AI-powered dialysis machine, aims to revolutionise kidney care in India

Bengaluru-based Renalyx Health Systems, a technology innovation company in renal care, has developed a fully indigenous haemodialysis machine, 'Renalyx – RxT 21', claimed to be the first in the world with AI and cloud-based smart technologies.

Renalyx will be the sixth company globally, and the first in India, to produce an advanced dialysis machine with EU CE certification. Renalyx plans to invest ₹800 crore in the next four years to build a manufacturing capacity of 5,000 machines a year by FY25-26 and an additional capacity of 1,500 machines by FY27-28, said Dr. Shyam Vasudeva Rao, Founder & Director of Renalyx Health Systems.

“Our cutting-edge haemodialysis machine will revolutionise renal care by making dialysis facilities affordable and accessible, thus strengthening the kidney healthcare infrastructure of the country. Our indigenously developed haemodialysis machine will play a game-changing role in reducing dialysis expenses. We will scale up our manufacturing capacity and reduce the Total Cost of Ownership of RxT 21 by 40% compared to that of imported machines,” he said.

Renalyx has manufacturing facilities at Bengaluru and Mysuru in Karnataka, and at Mumbai in Maharashtra, to support its scale-up plans.

The machines are equipped with advanced features such as Integrated Nephrology Information System (NIS) on the cloud, AI-based smart algorithms, Electronic Medical Records (EMR) integration, remote diagnostics and alerts through real-time telemetry, advanced image processing, and Internet of Medical Things (IoMT) capabilities for continuous performance monitoring and clinical oversight. These will help doctors remotely access patients’ EMR, current settings of the dialysis machine, and patients’ critical event history to take action and advise necessary treatment and care. Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres, and hospitals to make renal care available to a large number of people.

Initially, the machine will be priced at ₹6.70 lakh, significantly lower than the imported machines. The machine has the latest technologies, including cloud-based telenephrology platforms, to offer safety and quality care to kidney patients—end-stage renal disease (ESRD) patients, especially those with cardiovascular, pulmonary, and acute kidney injury-related issues.

“We have plans to develop a broader range of technologically advanced machines over the next three years, including a home dialysis model,” said Dr. Shyam Vasudeva Rao.

In addition, Renalyx has awarded a manufacturing license for three years to Bharat Electronics (BEL) to produce 6,000 Renalyx–RxT 17 machines, a previously launched dialysis machine with standard features and facilities.

According to Pradhan Mantri National Dialysis Program (PMNDP) data, approximately 2.2 lakh new cases of End-Stage Renal Disease (ESRD) are reported in India each year, creating an additional demand for 3.4 crore dialysis sessions annually.